

FOI 3230

13th August 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq)

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Avelumab (Bavencio)

Response:

3 patients

Carboplatin single agent or in any other combination

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Carboplatin with Gemcitabine

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Carboplatin with Gemcitabine + Avelumab (Bavencio)

Response:

3 patients as above

Carboplatin with Paclitaxel

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Cisplatin single agent or in any other combination

Response:

0

Cisplatin with Gemcitabine

Response:

0

Cisplatin with Gemcitabine + Nivolumab (Opdivo)

Response:

0

Cisplatin with Gemcitabine + Avelumab (Bavencio)

Response:

0

Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)

Response:

0

Nivolumab (Opdivo)

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Pembrolizumab (Keytruda)

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Other active systemic anti-cancer therapy

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this

information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.- unable to answer from pharmacy system alone- manual trawl required

Palliative care only

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Erdafitinib

Response:

0

Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

The Southern Health and Social Care Trust is not currently participating in any clinical trials for the treatment of urothelial cancer.

Email: Foi.Team@Southerntrust.hscni.net